Chiesi Farmaceutici S.p.A.: all 299 studies
Page 3 of 3. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001CompletedNCT02386761Phase 1
- Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy VolunteersCompletedNCT02359292Phase 1
- Evaluation of Metabolic Profile of OC000459CompletedNCT02341521Phase 1
- First in Man Evaluation of Single and Multiple Doses of Oral ATX2417CompletedNCT02316912Phase 1
- Drug-drug Interaction Study of CHF5993 With CimetidineCompletedNCT02287272Phase 1
- A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DMECompletedNCT02193113Phase 1
- Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected SubjectsCompletedNCT02191657Phase 1
- Efficacy and Safety of Glycopyrrolate Bromide of COPD PatientsCompletedNCT02189577Phase 2
- A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThalerCompletedNCT02148120Phase 2
- LOWER: Lomitapide Observational Worldwide Evaluation RegistryCompletedNCT02135705
- AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)CompletedNCT02123667
- Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® DeviceCompletedNCT02119247Phase 1
- Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD PatientsCompletedNCT02119234Phase 1
- A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.CompletedNCT02040597Phase 1
- An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPICompletedNCT02018549Phase 2
- A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD PatientsCompletedNCT02000609Phase 2
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseaseCompletedNCT01911364Phase 3
- Lamazym Aftercare StudyCompletedNCT01908725Phase 3
- Lamazym Aftercare Study FR Designed to Provide Treatment for French PatientsCompletedNCT01908712Phase 3
- Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years OldCompletedNCT01848769Phase 2
- Active Drug Surveillance Program of Ferriprox UseCompletedNCT01838291
- Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult PatientsCompletedNCT01803087Phase 2
- Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation PowderCompletedNCT01738087Phase 2
- Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD PatientsCompletedNCT01730404Phase 2
- Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)CompletedNCT01703052Phase 1
- beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR StudyCompletedNCT01691677Phase 3
- A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in AsthmaticsCompletedNCT01689571Phase 2
- A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisCompletedNCT01681953Phase 3
- Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-MannosidosisCompletedNCT01681940Phase 2
- Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic ChildrenWithdrawnNCT01658891Phase 3
- An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) DeviceCompletedNCT01651650Phase 2
- First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress SyndromeCompletedNCT01651637Phase 1
- Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000CompletedNCT01651455
- Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension PhaseCompletedNCT01602393Phase 2
- Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPDCompletedNCT01584505Phase 2
- Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic ChildrenCompletedNCT01584492Phase 2
- Prevalence and Reversibility of Lung Hyperinflation in AsthmaCompletedNCT01573364
- A Study in Patients With AsthmaCompletedNCT01570478Phase 3
- International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison)CompletedNCT01567280
- Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and GlycopyrrolateCompletedNCT01476813Phase 2
- Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic ChildrenCompletedNCT01475032Phase 3
- Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years OldCompletedNCT01468272Phase 2
- Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic ChildrenCompletedNCT01450774Phase 3
- Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)CompletedNCT01421056Phase 2
- Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy VolunteersCompletedNCT01398111Phase 1
- Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer DevicesCompletedNCT01370031Phase 2
- A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)TerminatedNCT01351792Phase 3
- Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDICompletedNCT01349257Phase 2
- Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal OsteoporosisCompletedNCT01348243Phase 3
- Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic PatientsCompletedNCT01345916Phase 3
- Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD PatientsCompletedNCT01344655Phase 4
- Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)CompletedNCT01343745Phase 2
- Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor SitesCompletedNCT01294254Phase 2
- Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisStatus unknownNCT01285700Phase 2
- Foster With or Without Charcoal Block or Aerochamber PlusCompletedNCT01280175Phase 1
- Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisCompletedNCT01268358Phase 1
- A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.CompletedNCT01191424Phase 2
- Safety and Efficacy Study of Glyco pMDI After Single and Repeated AdministrationCompletedNCT01176903Phase 1/2
- Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy VolunteersCompletedNCT01176851Phase 1
- Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD PatientsCompletedNCT01176747Phase 1/2
- Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS NebulizerCompletedNCT01116089Phase 1
- A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®CompletedNCT01111383Phase 3
- Prospective Study on Asthma ControlCompletedNCT01110460
- Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)CompletedNCT01102543
- Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent AsthmaCompletedNCT01070524Phase 2
- The Natural History of Infantile Globoid Cell LeukodystrophyCompletedNCT00983879
- Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00972140Phase 3
- Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate CroupTerminatedNCT00938353Phase 3
- BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)CompletedNCT00929851Phase 3
- FACTO Study (Foster® As Complete Treatment Option)CompletedNCT00901368Phase 4
- A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's AtaxiaCompletedNCT00897221Phase 2
- Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic PatientsCompletedNCT00868023Phase 2
- A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe AsthmaCompletedNCT00862394Phase 3
- Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent AsthmaCompletedNCT00862264Phase 3
- Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00782535Phase 2
- Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy VolunteersCompletedNCT00777595Phase 1
- Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00742248Phase 2
- A Pharmacokinetic (PK) Study of Extended-Release Epidural Morphine in Upper Abdominal SurgeryCompletedNCT00728832Phase 1
- Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPDCompletedNCT00640484Phase 2
- Dose Finding Study of CHF 4226 for Treating Patients With COPDCompletedNCT00605891Phase 2
- Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma PatientsCompletedNCT00534625Phase 2
- A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's AtaxiaCompletedNCT00530127Phase 1/2
- Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled AsthmaCompletedNCT00528723Phase 3
- Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap StudyCompletedNCT00501982Phase 4
- The Natural History of Alpha-MannosidosisCompletedNCT00498420
- Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma SymptomsCompletedNCT00497523Phase 3
- Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of AsthmaCompletedNCT00497237Phase 3
- Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICSTerminatedNCT00486343Phase 4
- Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent AsthmaCompletedNCT00476268Phase 3
- Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPDCompletedNCT00476099Phase 3
- Porphozym in the Treatment of Acute Attacks in AIPCompletedNCT00418795Phase 2/3
- Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)CompletedNCT00413387Phase 3
- EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDICompletedNCT00394368Phase 3
- Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot UlcersTerminatedNCT00387101Phase 3
- As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent AsthmaCompletedNCT00382889Phase 3
- Safety Study of Zileuton Injection in Patients With AsthmaCompletedNCT00299065Phase 1/2
- CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)TerminatedNCT00107666Phase 2
- Efficacy Study in Removing Excess Iron From the HeartCompletedNCT00105495Phase 4
- Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne VulgarisStatus unknownNCT00098358Phase 2